BAUSCH + LOMB CORP

Board expansion, new CEO on board and bullish analyst outlook boost Bausch + Lomb’s growth prospects—eye‑health leader eyes a 26% upside for investors.

Discover how Bausch + Lomb’s Q2 2026 earnings jumped 70%, revenue grew 13%, and the company’s upbeat guidance points to stronger shareholder value and eye‑care innovation.

BL1107 phase‑2 failure forces Bausch + Lomb to pivot away from glaucoma, refocusing on proven eye‑care products and new R&D prospects.

Bausch + Lomb, a global eye health leader, is facing turbulence after two key board members resigned and the company’s agreement with billionaire investor Carl Icahn was terminated.

Bausch + Lomb Corporation reported strong Q2 2025 results, with revenue growth of 5% and adjusted EBITDA of $191 million, despite facing a product recall.